Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 84 matches for

Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.

To the left, the OBN Awards logo and the Alchemab Therapeutics logo are on a deep purple background. To the right, there is an image of London overlooking the River Thames. Glitter is falling from the sky.

Dr Quin Wills appointed as Ochre Bio CEO

Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO.

Ochre Bio appoints ex-Eli Lilly and AstraZeneca VP as Non-Executive Director

The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics.

PepGen to focus on development of promising DM1 program following 10 mg/kg PGN-EDO51 update

PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs. PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild. DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.

Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer

Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company harnessing the power of non-coding human genetics to discover first-in-class antibody treatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business Officer with immediate effect.

PepGen appoints Kasra Kasraian, PhD, as Chief Technology Officer

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies.

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company

Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.

Enara Bio strengthens senior leadership with key Executive and Board appointments alongside acceleration of multiple T-Cell engager programs

Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen® and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financial Officer (CFO). Her appointment strengthens the leadership team at a key moment for Enara as it prepares to transition its lead assets towards clinical development. Stacey most recently served as CBO at Xilio Therapeutics, where she was the architect of a series of major pharma collaborations. In total, Stacey brings over 25 years of experience in delivering growth, innovation, and strategic transformation in the biotech and pharmaceutical industries.

PepGen announces appointment of two new directors to its Board

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.

Moa named one of TIME's top greentech companies in 2025

Moa recognised as leading global innovator in environmental impact.

Moa forms new biological partnership with NAICONS

Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides.

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.

Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen® biology and expression

Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio’s pipeline of TCR-based immunotherapies targeting Dark Antigens®

Enara Bio listed in the inaugural edition of The Sunday Times 100 Tech 2025

The guide showcases Britain's fastest-growing private tech companies from The Sunday Times, commercialising innovation across the UK. "This recognition is a testament to our innovative science and the hard work of our incredible team as we strive to develop safe and effective treatments for cancer patients." Enara Bio

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS

The agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.

Theolytics appoints David Apelian MD, PhD, MBA as CEO

David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer.

OMass Therapeutics strengthens its leadership team with the promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-Clinical

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that the Company has promoted Dr Hsin Loke to Chief Operating Officer (COO) and Jon Roffey Ph.D. to Senior Vice President, Discovery and Non-Clinical, effective immediately.

Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC).

OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Professor Steven Charlton as Chief Scientific Officer (CSO), effective 1 December 2024. He will take on the role from Dr Ali Jazayeri, who is leaving OMass to pursue other opportunities.

CyanoCapture at the forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture

CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.

Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson to map genetic associations linked to autoimmune disease

Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using 3D genomics to discover precision medicines for complex diseases, announces today it has entered a research collaboration with Johnson & Johnson*.

Load More

Similar stories